本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Kiniksa Pharmaceuticals Ltd.

35.68
+0.17000.48%
成交量:20.05万
成交额:712.19万
市值:26.44亿
市盈率:540.31
高:35.84
开:35.53
低:35.12
收:35.51
52周最高:35.84
52周最低:17.82
股本:7,410.77万
流通股本:3,355.22万
量比:0.56
换手率:0.60%
股息:- -
股息率:- -
每股收益(TTM):0.0660
每股收益(LYR):-0.6047
净资产收益率:1.03%
总资产收益率:0.46%
市净率:5.34
市盈率(LYR):-59.00

数据加载中...

2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/25

重要事件披露

Form 8-K - Current report
2024/06/14

重要事件披露

Form 8-K - Current report
2024/06/05

重要事件披露

Form 8-K - Current report
2024/04/25

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/23

重要事件披露

Form 8-K - Current report
2024/04/02

重要事件披露

Form 8-K - Current report
2024/03/29

重要事件披露

Form 8-K - Current report
2024/03/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/28

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/28

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/28

重要事件披露

Form 8-K - Current report
2024/02/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/15

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]